KEGG   DRUG: Ramucirumab
Entry
D09371                      Drug                                   
Name
Ramucirumab (USAN);
Ramucirumab (genetical recombination) (JAN);
Cyramza (TN)
Product
Formula
C6374H9864N1692O1996S46
Exact mass
143518.9522
Mol weight
143607.6508
Sequence
(Heavy chain)
EVQLVQSGGG LVKPGGSLRL SCAASGFTFS SYSMNWVRQA PGKGLEWVSS ISSSSSYIYY
ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARVT DAFDIWGQGT MVTVSSASTK
GPSVLPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PELLGGPSVF
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN
QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN
VFSCSVMHEA LHNHYTQKSL SLSPGK
(Light chain)
DIQMTQSPSS VSASIGDRVT ITCRASQGID NWLGWYQQKP GKAPKLLIYD ASNLDTGVPS
RFSGSGSGTY FTLTISSLQA EDFAVYFCQQ AKAFPPTFGG GTKVDIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H143-H199, H219-L214, H225-H'225, H228-H'228, H260-H320, H366-H424, H'22-H'96, H'143-H'199, H'219-L'214, H'260-H'320, H'366-H'424, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Remark
Therapeutic category: 4291
ATC code: L01FG02
Product: D09371<JP/US>
Efficacy
Antineoplastic, Anti-VEGF receptor 2 antibody
  Disease
Gastric cancer [DS:H00018]
Non-small cell lung cancer (EGFR exon 19 deletions or exon 21 (L858R) substitution mutated) [DS:H00014]
Colorectal cancer [DS:H00020]
Hepatocellular carcinoma [DS:H00048]
  Type
Monoclonal antibody
Target
VEGFR2 (KDR) [HSA:3791] [KO:K05098]
  Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa04014  Ras signaling pathway
hsa04370  VEGF signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
     L01FG02 Ramucirumab
      D09371  Ramucirumab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Ramucirumab
    D09371  Ramucirumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D09371  Ramucirumab (USAN); Ramucirumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   VEGFR family
    VEGFR2 (KDR)
     D09371  Ramucirumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09371
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09371
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09371
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09371
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D09371
Other DBs
CAS: 947687-13-0
PubChem: 96026051
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system